Podcasts about oncology power hour

Guest: Edward B. Garon, MD Could a new standard of treatment be on the horizon for patients with HER2 mutated NSCLC? Dr. Edward Garon, a Thoracic Medical Oncologist at UCLA Health, shares key takeaways on non-small cell lung cancer from the ESMO 2021 Congress.

Guest: James G. Christensen, MD Catch up on how new research presented at the 2021 ESMO Congress is helping to evolve targeted therapies for colorectal and pancreatic cancer with Dr. James G. Christensen.

Host: Jennifer Caudle, DO Guest: Tracey Evans, MD Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients. In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented 18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; P

Host: Jennifer Caudle, DO Guest: Tracey Evans, MD Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients. In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented 18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; P

Guest: Amit Bobby Mahajan, MD, FCCP, DAABIP Lung cancer is known to be the deadliest and second most common cancer in men and women. Although there currently isn’t a cure, the last decade has shown great improvements and hope for the treatment of non-small cell lung cancer, as Dr. Bobby Mahajan explains.

Guest: Amit Bobby Mahajan, MD, FCCP, DAABIP Lung cancer is known to be the deadliest and second most common cancer in men and women. Although there currently isn’t a cure, the last decade has shown great improvements and hope for the treatment of non-small cell lung cancer, as Dr. Bobby Mahajan explains.

Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD Since treatment outcomes vary greatly between lung cancer patients—even among those who are diagnosed at the same stages of disease—much research has been devoted to finding biomarkers that identify patients who are most likely to develop metastatic disease. Here to walk us through a promising line of research with hopes of adding the first serum biomarker to the fight against non-small cell lung cancer is Dr. Tony Hu, professor and Weatherhead Presidential chair in Biotechnology Innovation at Tulane University Medical School.

Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD One of the biggest blindspots for those who care for patients with lung cancer is not knowing whose disease is going to metastasize quickly and who, by extension, would benefit from the most aggressive treatments up front. But the entrance of better detection methods, such as biomarkers and assay tests, could change all of that, as Dr. Tony Hu explains.

Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD One of the biggest blindspots for those who care for patients with lung cancer is not knowing whose disease is going to metastasize quickly and who, by extension, would benefit from the most aggressive treatments up front. But the entrance of better detection methods, such as biomarkers and assay tests, could change all of that, as Dr. Tony Hu explains.

Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD Since treatment outcomes vary greatly between lung cancer patients—even among those who are diagnosed at the same stages of disease—much research has been devoted to finding biomarkers that identify patients who are most likely to develop metastatic disease. Here to walk us through a promising line of research with hopes of adding the first serum biomarker to the fight against non-small cell lung cancer is Dr. Tony Hu, professor and Weatherhead Presidential chair in Biotechnology Innovation at Tulane University Medical School.

Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD One of the biggest blindspots for those who care for patients with lung cancer is not knowing whose disease is going to metastasize quickly and who, by extension, would benefit from the most aggressive treatments up front. But the entrance of better detection methods, such as biomarkers and assay tests, could change all of that, as Dr. Tony Hu explains.

Guest: Amit Bobby Mahajan, MD, FCCP, DAABIP Lung cancer is known to be the deadliest and second most common cancer in men and women. Although there currently isn’t a cure, the last decade has shown great improvements and hope for the treatment of non-small cell lung cancer, as Dr. Bobby Mahajan explains.

Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD Since treatment outcomes vary greatly between lung cancer patients—even among those who are diagnosed at the same stages of disease—much research has been devoted to finding biomarkers that identify patients who are most likely to develop metastatic disease. Here to walk us through a promising line of research with hopes of adding the first serum biomarker to the fight against non-small cell lung cancer is Dr. Tony Hu, professor and Weatherhead Presidential chair in Biotechnology Innovation at Tulane University Medical School.

Guest: Jason Day Guest: Dening Day Biomarker testing is a critical step in any mNSCLC patient’s treatment journey, as PGA champion Jason Day found out when his mother, Dening, was diagnosed with the disease.1-3 In this video, Jason and Dening tell their story about how biomarker testing helped Dening get on a therapy that can target the driver of her disease. Jason and Dening’s story may help your newly diagnosed mNSCLC patients understand the importance of testing their lung cancer, knowing the full molecular results, and treating based on those results. Share this video and more with your patients by visiting TestLungCancer.com. References: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.3.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J ...

Guest: Jason Day Guest: Dening Day Biomarker testing is a critical step in any mNSCLC patient’s treatment journey, as PGA champion Jason Day found out when his mother, Dening, was diagnosed with the disease.1-3 In this video, Jason and Dening tell their story about how biomarker testing helped Dening get on a therapy that can target the driver of her disease. Jason and Dening’s story may help your newly diagnosed mNSCLC patients understand the importance of testing their lung cancer, knowing the full molecular results, and treating based on those results. Share this video and more with your patients by visiting TestLungCancer.com. References: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.3.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J ...

Host: Jennifer Caudle, DO Guest: Kristin Higgins, MD Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment. US-32345 Last Updated 12/19

Host: Jennifer Caudle, DO Guest: Kristin Higgins, MD Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment. US-32345 Last Updated 12/19

Host: Jennifer Caudle, DO Guest: Alexander Whitley, MD Guest: Alejandro Calvo, MD Guest: Kim Rohan, MS APN, AOCN At the 2019 ASTRO Annual Meeting, radiation oncologist Dr. Alexander Whitley, medical oncologist Dr. Alejandro Calvo, and nurse practitioner Kim Rohan came together to share their experiences working as part of a multidisciplinary team to care for patients with unresectable Stage III non-small cell lung cancer. US-32360 Last Updated 12/19

Host: Jennifer Caudle, DO Guest: Kristin Higgins, MD Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment. US-32345 Last Updated 12/19

Host: Jennifer Caudle, DO Guest: Alexander Whitley, MD Guest: Alejandro Calvo, MD Guest: Kim Rohan, MS APN, AOCN At the 2019 ASTRO Annual Meeting, radiation oncologist Dr. Alexander Whitley, medical oncologist Dr. Alejandro Calvo, and nurse practitioner Kim Rohan came together to share their experiences working as part of a multidisciplinary team to care for patients with unresectable Stage III non-small cell lung cancer. US-32360 Last Updated 12/19

Host: Jennifer Caudle, DO Guest: Alexander Whitley, MD Guest: Alejandro Calvo, MD Guest: Kim Rohan, MS APN, AOCN At the 2019 ASTRO Annual Meeting, radiation oncologist Dr. Alexander Whitley, medical oncologist Dr. Alejandro Calvo, and nurse practitioner Kim Rohan came together to share their experiences working as part of a multidisciplinary team to care for patients with unresectable Stage III non-small cell lung cancer. US-32360 Last Updated 12/19

Host: Jennifer Caudle, DO Guest: Timothy Kruser, MD Recorded live at the 2019 ASTRO Annual Meeting in Chicago, Illinois, tune in to hear Dr. Timothy Kruser share key updates from the PACIFIC study. IMFINZI® (durvalumab) is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Select Safety Information: Serious, potentially fatal risks were seen with IMFINZI in the PACIFIC trial. The most frequent serious adverse events (occurring in greater than or equal to 2% of patients) were pneumonitis or radiation pneumonitis and pneumonia. Immune-mediated adverse reactions, including immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies (including thyroid disorders, adrenal insufficiency, type 1 diabetes, and hypophysitis), nephritis, dermatologic reactions, and other immune-mediated adverse reactions, infection, and infusion-related reactions were reported in patients receiving IMFINZI in the PACIFIC trial. Scroll for additional Important Safety Information and Link to PI. US-36842 Last Updated 05/20

Host: Jennifer Caudle, DO Guest: Timothy Kruser, MD Recorded live at the 2019 ASTRO Annual Meeting in Chicago, Illinois, tune in to hear Dr. Timothy Kruser share key updates from the PACIFIC study. IMFINZI® (durvalumab) is indicated for the treatment of adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Select Safety Information: Serious, potentially fatal risks were seen with IMFINZI in the PACIFIC trial. The most frequent serious adverse events (occurring in greater than or equal to 2% of patients) were pneumonitis or radiation pneumonitis and pneumonia. Immune-mediated adverse reactions, including immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies (including thyroid disorders, adrenal insufficiency, type 1 diabetes, and hypophysitis), nephritis, dermatologic reactions, and other immune-mediated adverse reactions, infection, and infusion-related reactions were reported in patients receiving IMFINZI in the PACIFIC trial. Scroll for additional Important Safety Information and Link to PI. US-36842 Last Updated 05/20

Host: Jenn Simmons, MD Guest: Clark C. Chen, MD, PhD Guest: David Piccioni, MD, PHD Guest: Christina I. Tsien, MD There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni. ©2019 Tocagen. All rights reserved. VV-REG-003123 10/19

Host: Jenn Simmons, MD Guest: Clark C. Chen, MD, PhD Guest: David Piccioni, MD, PHD Guest: Christina I. Tsien, MD There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni. ©2019 Tocagen. All rights reserved. VV-REG-003123 10/19

Host: Jenn Simmons, MD Guest: Clark C. Chen, MD, PhD Guest: David Piccioni, MD, PHD Guest: Christina I. Tsien, MD There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni. ©2019 Tocagen. All rights reserved. VV-REG-003123 10/19

Host: Jenn Simmons, MD Guest: Clark C. Chen, MD, PhD Guest: David Piccioni, MD, PHD Guest: Christina I. Tsien, MD There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni. ©2019 Tocagen. All rights reserved. VV-REG-003123 10/19

Guest: Christine Bestvina, MD Even in early-stage disease, the recurrence rate for non-small cell lung cancer can be as high as 30 to 50 percent. Hear from oncologist Dr. Christine Bestvina on how she manages patients with recurrent disease. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Guest: Christine Bestvina, MD Determining how to treat your non-small cell lung cancer patients is a critical part of their care. Joining us to explore treatment modalities for her patients based on their cancer stage is Dr. Christine Bestvina, an oncologist and Assistant Professor of Medicine at the University of Chicago. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Guest: Christine Bestvina, MD Oncologist Dr. Chistine Bestvina addresses therapeutic and supportive care priorities for patients with progressive metastatic non-small cell lung cancer. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Guest: Christine Bestvina, MD Even in early-stage disease, the recurrence rate for non-small cell lung cancer can be as high as 30 to 50 percent. Hear from oncologist Dr. Christine Bestvina on how she manages patients with recurrent disease. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Host: Jennifer Caudle, DO Guest: Erin Schenk MD, PhD Through prevention recommendations and various diagnostic tools, the ability to detect non-small cell lung cancer (NSCLC) early and, by extension, dramatically improve a patient’s quality of life is now achievable. And here to walk Dr. Jennifer Caudle through all of that is Dr. Erin Schenk, an Assistant Professor of Medical Oncology at the University of Colorado. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Host: Jennifer Caudle, DO Guest: Erin Schenk MD, PhD The lingering fear of CT-based screenings delivering false positives has caused many challenges, but that doesn’t mean achieving accurate diagnostic staging with our non-small cell lung cancer patients is impossible. To prove it, Dr. Erin Schenk walks through the steps she takes to determine a patient’s stage of cancer and how it impacts her treatment approach. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Guest: Christine Bestvina, MD Determining how to treat your non-small cell lung cancer patients is a critical part of their care. Joining us to explore treatment modalities for her patients based on their cancer stage is Dr. Christine Bestvina, an oncologist and Assistant Professor of Medicine at the University of Chicago. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Guest: Christine Bestvina, MD Oncologist Dr. Chistine Bestvina addresses therapeutic and supportive care priorities for patients with progressive metastatic non-small cell lung cancer. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Host: Jennifer Caudle, DO Guest: Erin Schenk MD, PhD The lingering fear of CT-based screenings delivering false positives has caused many challenges, but that doesn’t mean achieving accurate diagnostic staging with our non-small cell lung cancer patients is impossible. To prove it, Dr. Erin Schenk walks through the steps she takes to determine a patient’s stage of cancer and how it impacts her treatment approach. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Host: Jennifer Caudle, DO Guest: Erin Schenk MD, PhD Through prevention recommendations and various diagnostic tools, the ability to detect non-small cell lung cancer (NSCLC) early and, by extension, dramatically improve a patient’s quality of life is now achievable. And here to walk Dr. Jennifer Caudle through all of that is Dr. Erin Schenk, an Assistant Professor of Medical Oncology at the University of Colorado. Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Host: Chrysalyne D. Schmults, MD, MSCE (Chair) Guest: Omid Hamid, MD Guest: Anokhi Jambusaria, MD, MSCE, FAAD Please note: This activity is no longer available for continuing education credit. The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a cSCC survivor draws upon his experience with the cancer when surgery and chemotherapy failed him, as our multidisciplinary faculty panel focus on how to optimally select patients with cSCC for treatment with immunotherapy.

Host: Chrysalyne D. Schmults, MD, MSCE (Chair) Guest: Omid Hamid, MD Guest: Anokhi Jambusaria, MD, MSCE, FAAD Please note: This activity is no longer available for continuing education credit. The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a cSCC survivor draws upon his experience with the cancer when surgery and chemotherapy failed him, as our multidisciplinary faculty panel focus on how to optimally select patients with cSCC for treatment with immunotherapy.

Get a closer look at the newest development in cancer immunotherapy: the bifunctional fusion protein. Could this small but mighty protein designed to block two signaling pathways used by tumor cells to escape immune system control be the key to managing both tumor growth and metastasis? For more episodes in this series, visit ReachMD.com/IO.

Host: Maurice Pickard, MD Guest: Olufunmilayo (Funmi) Olopade, MD, FACP Host Dr. Maurice Pickard welcomes Dr. Funmi Olopade, Walter L. Palmer Distinguished Service Professor in Medicine and Human Genetics, Director of the Hematology/Oncology Fellowship Program, and Director of the Center for Clinical Cancer Genetics at the University of Chicago. Dr. Olopade discusses disparities in health outcomes for black women with breast cancer. Dr. Olopade is an expert in cancer risk assessment and individualized treatment for the most aggressive forms of breast cancer, having developed novel management strategies based on an understanding of the altered genes in individual patients. She stresses comprehensive risk reduction and prevention strategies in high-risk populations, as well as earlier detection through advanced imaging technologies.

Host: Maurice Pickard, MD Guest: Olufunmilayo (Funmi) Olopade, MD, FACP Host Dr. Maurice Pickard welcomes Dr. Funmi Olopade, Walter L. Palmer Distinguished Service Professor in Medicine and Human Genetics, Director of the Hematology/Oncology Fellowship Program, and Director of the Center for Clinical Cancer Genetics at the University of Chicago. Dr. Olopade discusses disparities in health outcomes for black women with breast cancer. Dr. Olopade is an expert in cancer risk assessment and individualized treatment for the most aggressive forms of breast cancer, having developed novel management strategies based on an understanding of the altered genes in individual patients. She stresses comprehensive risk reduction and prevention strategies in high-risk populations, as well as earlier detection through advanced imaging technologies.

Guest: Alan Astrow, MD Host: Leslie P. Lundt, MD All the technology and advances in medical science hasn't changed the most difficult thing we do as physicians - relay emotionally charged diagnostic and prognostic information to our patients. How can we do a better job? Communication skills do not automatically improve with increasing physician experience. Dr. Alan Astrow, the director of the division of hematology and medical oncology at Maimonides Cancer Center in New York City explains how we can break bad news to patients in a more effective and supportive way.